The diabetic foot ulcers treatment market has emerged as a promising therapeutic area. Diabetic foot ulcers refer to open sores or wounds that occur in approximately 15% of all patients with diabetes and precede 84% of diabetes-related lower-leg amputations. The exact causes of diabetic foot ulcers are peripheral neuropathy or nerve damage, foot deformities, and poor circulation. The primary goal of therapies is to promote wound healing by managing infection, reducing inflammation, and increasing blood flow to the wound. The global diabetic foot ulcers treatment market is estimated to be valued at US$ 7.72 Bn in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the diabetic foot ulcers treatment are 3M Healthcare, Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, Molnlycke Health Care AB, Alkem Laboratories Ltd., Healthium Medtech, Kerecis, Podimetrics, Carmell Corporation, Paracrine, Inc., VIVEX Biologics, Inc., and PolarityTE, Inc. These players are focusing on new product launches and strategic collaborations to strengthen their market position.

The key opportunities in the market include rising healthcare expenditures in developing nations, increasing public-private investments to create awareness about diabetic foot ulcers treatment and prevention. Advancements in wound care practices, therapies and technologies are creating new growth prospects.

Globally, there is high demand for diabetic foot ulcers treatment solutions particularly in the Asia Pacific region owing to the increasing prevalence of diabetes. Many players are exploring opportunities in Southeast Asian, South Asian and Latin American markets to leverage unmet needs and tap into high growth regions.

Market Drivers
Rising prevalence of diabetes: According to IDF Diabetes Atlas 2021, approximately 537 million adults were living with diabetes and the condition resulted in 6.7 million deaths globally in 2021. This rising burden of diabetes and associated complications is a major driver.

Advancements in wound care products and therapies: Introduction of innovative product formulations for improved healing and reduced risk of amputations is fueling the market growth. Products featuring silver technology, growth factors and skin substitutes are gaining popularity.

Market Restraints
High cost of advanced treatment procedures: Many new devices, dressings and therapies are expensive which make them unaffordable for patients in low-income settings. This acts as a key restraint for market expansion in underdeveloped regions.

Lack of reimbursement and insurance coverage: Despite the massive costs associated with diabetes treatment and foot care, many countries lack universal coverage for these Medical expenses. This factor limits access to standard and innovative treatment options.

Segment Analysis
The diabetic foot ulcers treatment market is segmented into wound care dressings, wound care devices, active therapies, and others. Amongst these, wound care dressings dominates the diabetic foot ulcers treatment market due to increasing cases of diabetic foot ulcers coupled with rising adoption of advanced wound care dressings like hydrocolloid dressings, alginate dressings, foam dressings, hydrogel dressings, and film & contact layer dressings for effective management of diabetic foot ulcers. Hydrocolloid dressings have a significant share as they provide protection against external infection, absorb exudate, and maintain a moist environment required for healing.

The active therapies segment is expected to grow at a significant rate during the forecast period. This is attributed to increasing adoption of advanced therapies like hyperbaric oxygen therapy, growth factors therapy, and stem cell therapy for the treatment of diabetic foot ulcers. Growth factors therapy aids faster healing by stimulating angiogenesis and cell proliferation. Stem cells therapy aids regeneration of new tissues.

Global Analysis

Regionally, North America dominates the  global diabetic foot ulcers treatment market  and is expected to continue its dominance during the forecast period. This is attributed to the rising incidences of diabetic foot ulcers, developed healthcare infrastructure, availability of advanced treatment options and favorable reimbursement policies in the region. Additionally, the Asia Pacific region is anticipated to witness the highest growth during the forecast period. This is due to increasing healthcare expenditure, growing geriatric population, rising prevalence of diabetes and growing awareness regarding treatment of diabetic foot ulcers in emerging nations like India and China.